Details

Last Funding Type

Grant

Last Funding Money Raised

€50K

Industries

Biotechnology,Clinical Trials,Health Care,Medical

Founded date

Jan 1, 2014

Number Of Employee

1 - 10

Operating Status

Active

Medicortex Finland is developing the first, non-invasive, point-of-care diagnostic test for Traumatic Brain Injury and concussion.

Problem: A Traumatic Brain Injury (TBI) happens when an external force to the head causes damage to the brain tissue. Mild TBI, which is also known as concussions, are difficult to diagnose with current diagnostic methods such as CT and MRI scans.

Solution: Medicortex is working towards the identification of brain injury biomarkers and their incorporation into a hand-held diagnostic kit, which will give a reliable result rapidly and will not require medical professionals to interpret the result.

Business: We identified a unique biomarker that can be detected from urine and saliva. With strong clinical evidence and protected idea, we are willing to negotiate with bigger diagnostic companies for collaboration on manufacturing and distribution.

Market: Customers include hospitals, emergency rooms, paramedics and first responders, military paramedics, sports teams (especially contact sports such as rugby, American football, ice hockey), pharma and insurance companies.

Accomplishments: We have reached Phase II Clinical studies of the biomarker. The company received grant funding from US Department of Defense, European Union and Finnish Government.